{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=9&sponsor=Sanofi", "query": { "sponsor": "Sanofi", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 133, "total_pages": 14, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=10&sponsor=Sanofi&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=8&sponsor=Sanofi&page_size=10" }, "source": "local", "last_synced_at": "2026-10-16T02:51:08.409Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06660667", "title": "A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "Diluent", "type": "DRUG" }, { "name": "SAR402663", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 66, "start_date": "2024-11-21", "completion_date": "2031-06-30", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-08-15T18:19:30.868Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06660667" }, { "nct_id": "NCT05222906", "title": "Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gaucher's Disease Type III" ], "interventions": [ { "name": "Venglustat", "type": "DRUG" }, { "name": "imiglucerase", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 43, "start_date": "2022-04-18", "completion_date": "2026-10-30", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-21T00:11:45.701Z", "location_count": 4, "location_summary": "New Haven, Connecticut • Iowa City, Iowa • Dallas, Texas + 1 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Dallas", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05222906" }, { "nct_id": "NCT06407934", "title": "A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dermatitis Atopic" ], "interventions": [ { "name": "Amlitelimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1541, "start_date": "2024-05-08", "completion_date": "2027-03-17", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-10-16T02:51:08.409Z", "location_count": 82, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 67 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06407934" }, { "nct_id": "NCT02843035", "title": "Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gaucher Disease Type 1", "Gaucher Disease Type 3" ], "interventions": [ { "name": "imiglucerase", "type": "DRUG" }, { "name": "venglustat (GZ402671)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2017-01-04", "completion_date": "2026-10-30", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-07-29T06:41:36.039Z", "location_count": 3, "location_summary": "New Haven, Connecticut • Dallas, Texas • Fairfax, Virginia", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Dallas", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02843035" }, { "nct_id": "NCT06111586", "title": "Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Frexalimab", "type": "DRUG" }, { "name": "Insulin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "6 Years to 35 Years" }, "enrollment_count": 197, "start_date": "2023-12-11", "completion_date": "2030-10-29", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-08-01T10:22:41.138Z", "location_count": 14, "location_summary": "San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06111586" }, { "nct_id": "NCT05280548", "title": "A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fabry Disease" ], "interventions": [ { "name": "Agalsidase alfa", "type": "DRUG" }, { "name": "Agalsidase beta (GZ419828)", "type": "DRUG" }, { "name": "Migalastat", "type": "DRUG" }, { "name": "Venglustat (GZ402671)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 104, "start_date": "2022-05-03", "completion_date": "2027-12-06", "has_results": false, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-07-30T10:39:12.165Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Hawthorne", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05280548" }, { "nct_id": "NCT04848779", "title": "A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Glycogen Storage Disease Type II" ], "interventions": [ { "name": "Alglucosidase alfa GZ419829", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Days", "maximum_age": "6 Months", "sex": "ALL", "summary": "0 Days to 6 Months" }, "enrollment_count": 16, "start_date": "2021-06-10", "completion_date": "2026-10-28", "has_results": false, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-07-29T09:16:31.854Z", "location_count": 5, "location_summary": "Hawthorne, New York • Durham, North Carolina • Cincinnati, Ohio + 2 more", "locations": [ { "city": "Hawthorne", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04848779" }, { "nct_id": "NCT05731128", "title": "A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colitis Ulcerative" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2023-01-12", "completion_date": "2027-02-22", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-07-31T13:54:09.875Z", "location_count": 27, "location_summary": "Apple Valley, California • Beverly Hills, California • Oxnard, California + 24 more", "locations": [ { "city": "Apple Valley", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Oxnard", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Thousand Oaks", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05731128" }, { "nct_id": "NCT05002777", "title": "Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Warm Autoimmune Hemolytic Anemia (wAIHA)" ], "interventions": [ { "name": "rilzabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2021-12-07", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-10-15T09:53:47.856Z", "location_count": 11, "location_summary": "Cerritos, California • Glendale, California • Long Beach, California + 7 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05002777" }, { "nct_id": "NCT06834360", "title": "A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Rhinosinusitis With Nasal Polyps" ], "interventions": [ { "name": "Itepekimab (SAR440340)", "type": "DRUG" }, { "name": "Mometasone furoate nasal spray (MFNS)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 216, "start_date": "2025-02-06", "completion_date": "2027-10-11", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-10-14T01:32:23.393Z", "location_count": 15, "location_summary": "Birmingham, Alabama • La Mesa, California • Los Angeles, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Mesa", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Napa", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06834360" } ] }